BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial.

ABSTRACT:

Background

Replacement of carmustine (BCNU) in the BEAM regimen (BCNU, etoposide, cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell transplantation (ASCT) is feasible in lymphoma. However, randomised trials are lacking. Here, we present the first trial addressing this topic.

Methods

This multicentre, randomised, phase 2 study (BEB-trial) conducted at four haematological centres in Austria and Switzerland compares BEAM with BendaEAM in patients with relapsed lymphoma. Both regimens were administered intravenously before ASCT, in BEAM according to the standard protocol (300 mg/m² BCNU on day -6), in BendaEAM, BCNU was replaced by 200 mg/m² bendamustine given on days -7 and -6. Eligible patients were aged 18-75 years and had m

SUBMITTER: Keil F 

PROVIDER: S-EPMC10679477 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature